Seneca Biopharma Inc (NASDAQ:SNCA) Sees Significant Decrease in Short Interest

Seneca Biopharma Inc (NASDAQ:SNCA) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 51,300 shares, a decline of 59.5% from the June 15th total of 126,700 shares. Based on an average daily volume of 2,980,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.6% of the company’s shares are short sold.

An institutional investor recently bought a new position in Seneca Biopharma stock. Renaissance Technologies LLC acquired a new stake in Seneca Biopharma Inc (NASDAQ:SNCA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 258,884 shares of the company’s stock, valued at approximately $256,000. Renaissance Technologies LLC owned 6.70% of Seneca Biopharma at the end of the most recent reporting period. Institutional investors and hedge funds own 5.78% of the company’s stock.

Shares of NASDAQ:SNCA opened at $0.74 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.82 and a current ratio of 8.82. The company has a 50-day simple moving average of $0.86. Seneca Biopharma has a 1 year low of $0.50 and a 1 year high of $9.89.

Seneca Biopharma (NASDAQ:SNCA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.93) earnings per share (EPS) for the quarter. The business had revenue of $6.02 million during the quarter. Seneca Biopharma had a negative net margin of 212.36% and a negative return on equity of 212.68%.

Seneca Biopharma Company Profile

Seneca Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types.

Further Reading: What member countries make up the G-20?

Receive News & Ratings for Seneca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seneca Biopharma and related companies with's FREE daily email newsletter.